



( )

Acute lymphoblastic leukemia; ALL

1 600

80

90%

(minimal residual disease; MRD)

10 100 1 (10<sup>-4</sup>)  
S<sub>1</sub>

10 1 (10<sup>-5</sup>)  
( PCR )

33 80

2

( ) 100%

5

62%

2. 4 5 4 5

( ) 4 5 (A) (B) ( )

fl 七

Yuko Sekiya, Yinyan Xu, Hideki Muramatsu, Yusuke Okuno, Atsushi Narita, Kyogo Suzuki, Xinan Wang, Nozomu Kawashima, Hirotohi Sakaguchi, Nao Yoshida, Asahito Hama, Yoshiyuki Takahashi, Koji Kato, and Seiji Kojima. **Clinical utility of next-generation sequencing-based minimal residual disease in pediatric B-cell acute lymphoblastic leukemia.** *British Journal of Haematology*. 2016 11 11

10

**English ver.**

[http://www.med.nagoya-u.ac.jp/english01/dbps\\_data/material/nu\\_medical\\_en/res/all\\_20161118en.pdf](http://www.med.nagoya-u.ac.jp/english01/dbps_data/material/nu_medical_en/res/all_20161118en.pdf)